With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market.
Three biopharmaceuticals firms—Alumis (NASDAQ: ALMS), DBV Technologies S.A. (NASDAQ: DBVT), and Corcept Therapeutics Inc. (NASDAQ: CORT)—have staged significant rallies in 2025 that have either been unaffected by the market's recent seesawing or that remain up by a wide margin year-to-date as of Apr. 7. There is, of course, no telling whether these companies will have the momentum to keep these rallies going over the short or long term, but they nonetheless merit additional consideration.
